Drug Trial Radar · NCT05317416
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
Last checked: Nov 20, 2026Latest source record: Apr 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
854
Actual
Start
Mar 25, 2022
Primary completion
Aug 4, 2027
Study completion Oct 31, 2029
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Apr 7, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate whether elranatamab monotherapy can provide clinical benefit compared to lenalidomide monotherapy (control) in participants with newly diagnosed multiple myeloma after undergoing autologous stem cell transplant. In Part 1 and Part 2 of the study, participants in the study will either receive elranatamab (arm A and C) as an injection under the skin at the study clinic or lenalidomide orally once daily at home (arm B). Participation in the study will be approximately five years
Conditions
- Multiple Myeloma
Interventions
ElranatamabDrug
BCMA-CD3 bispecific antibody
LenalidomideDrug
Immunomodulatory drug
LenalidomideDrug
Immunomodulatory drug
ElranatamabDrug
BCMA-CD3 bispecific antibody
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free SurvivalTime frame: Assessed for up to approximately 5 years
Locations
209 sites in 27 countries. Site status is shown where the registry gives one.
Banner Gateway Medical Center
Gilbert, Arizona
Banner Gateway Medical Pavilion
Gilbert, Arizona
Banner MD Anderson Cancer Center
Gilbert, Arizona
Ronald Reagan UCLA Medical Center
Los Angeles, California
UCLA Department of Medicine - Hematology/Oncology
Los Angeles, California
UCLA Hematology/Oncology
Los Angeles, California
Santa Monica UCLA Medical Center & Orthopaedic Hospital
Santa Monica, California
UCLA Hematology/Oncology - Santa Monica
Santa Monica, California
Georgetown University Medical Center
Washington D.C., District of Columbia
Miami Cancer Institute at Baptist Health, Inc.
Miami, Florida
Winship Cancer Institute, Emory University
Atlanta, Georgia
Loyola University Chicago
Maywood, Illinois
Ascentist Doctor Hospital
Leawood, Kansas
University of Michigan
Ann Arbor, Michigan
American Oncology Partners, P.A. Dba MidAmerica Cancer Care
Kansas City, Missouri
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire
WMCHealth Advanced Physician Services
Hawthorne, New York
Westchester Medical Center
Valhalla, New York
Cleveland Clinic
Cleveland, Ohio
OhioHealth Arthur G.H. Bing, MD, Cancer Center
Columbus, Ohio
OhioHealth Research Institute
Columbus, Ohio
OhioHealth Riverside Methodist Hospital
Columbus, Ohio
Baylor University Medical Center
Dallas, Texas
Baylor Scott & White Medical Center - Temple
Temple, Texas
Slade Pharmacy
Richmond, Australia
Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia
Shoalhaven District Memorial Hospital
Nowra, New South Wales, Australia
Westmead Hospital
Westmead, New South Wales, Australia
Wollongong Hospital
Wollongong, New South Wales, Australia
Pindara Private Hospital
Benowa, Queensland, Australia
QScan Radiology Clinics
Clayfield, Queensland, Australia
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia
Epworth Healthcare
East Melbourne, Victoria, Australia
Precision Haematology
East Melbourne, Victoria, Australia
St Vincent's Hospital (Melbourne)
Fitzroy, Victoria, Australia
Medizinische Universität Wien
Vienna, Austria
ZNA Middelheim
Antwerp, Belgium
ZNA Cadix
Antwerp, Belgium
UZ Brussel
Brussels, Belgium
Institut Jules Bordet
Anderlecht, Bruxelles-capitale, Région de, Belgium
Showing 40 of 209 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.